Ischemix is a privately-held pharmaceutical company that is dedicated to advancing cytoprotective therapies for serious diseases and conditions. They have achieved significant accomplishments in the development of their novel compounds. In preclinical models of traumatic brain injury (TBI), Ischemix has demonstrated proof of concept with promising results.

Their treatments showed a significant improvement in sensorimotor and cognitive endpoints of learning and memory, as well as a reduction in brain lesion size and upregulation of mitochondrial energetics. Ischemix's cytoprotective compounds have also shown preclinical proof of concept in improving body movement using actigraphy technology. Furthermore, their drug candidate has a strong safety record, as demonstrated in a Phase 1 clinical trial.

Ischemix has received recognition for their innovations, including two awards totaling approximately $5 million from the US Department of Defense. With their commitment to research and development, Ischemix aims to bring effective therapies to those in need